CNAT News and Press, Conatus Pharmaceuticals From 02/15/19

My previous article forecast problems for selonsertib, as new research indicates that this drug targets mouse-specific pathways that are not present in humans. NASH cirrhosis trials continue to struggle. Intercept’s Ocaliva, a “NASH cirrhosis” drug candidate, is haile...

Market Assessment 2019 is seen as the year of NASH in the biotech industry. Intercept ( ICPT ) is expected to announce the top-line Phase 3 data readout for obeticholic acid in NASH fibrosis imminently. Likewise, top-line data readout is also expected in Q1/2019 from Conatus ( CNAT ). This s...

CAS Medical Systems (NASDAQ: CASM ) +54% on being acquired by Edwards Lifesciences. More news on: CAS Medical Systems, Inc., Ellie Mae, Inc., Coty Inc., Stocks on the move, Read more ...

Conatus Pharmaceuticals (NASDAQ: CNAT ) has completed enrollment in its Phase 2b clinical trial, ENCORE-LF , evaluating lead drug emricasan in patients with stable decompensated NASH cirrhosis. More news on: Conatus Pharmaceuticals, Healthcare stocks news, Read more ...

SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor. “With screen...

Viking Therapeutics (NASDAQ: VKTX ) +8.4% and Madrigal Pharmaceuticals (NASDAQ: MDGL )  +3.3% after-hours as Gilead’s (NASDAQ: GILD ) study designed to evaluate a chronic liver disease drug failed to meet its primary endpoint ; GILD -3.6% . More news on: Viking Therapeutic...

NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The Dow Jones Industrial Average was up 0.21 percent to close at 24,579.96, led higher by 3M and...

Gainers:  OncoCyte (NYSEMKT: OCX ) +228% . Voyager Therapeutics (NASDAQ: VYGR ) +36% . Conatus Pharmaceuticals (NASDAQ: CNAT ) +34% . Zynerba Pharmaceuticals (NASDAQ: ZYNE ) +33% . HyreCar (NASDAQ: HYRE ) +21% . Sanmina (NASDAQ: SANM ) +18% . Woodward (NASDAQ: WWD ) +17% . J &a...

Biocept (NASDAQ: BIOC ) +17%  on launching  liquid biopsy kits intended to broaden use of its proprietary technology platform for high sensitivity detection of circulating tumor DNA. More news on: Biocept, Inc., Pareteum Corporation, Conatus Pharmaceuticals, Stocks on the move,...

SAN DIEGO, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s completed Phase 2 clinical trials. Mitchell Schiffman, M.D., is the lead author on a new pub...